Terms: = Prostate cancer AND PAM50 AND Prognosis
4 results:
1. Molecular classifications of prostate cancer: basis for individualized risk stratification and precision therapy.
Ge Q; Li J; Yang F; Tian X; Zhang M; Hao Z; Liang C; Meng J
Ann Med; 2023; 55(2):2279235. PubMed ID: 37939258
[TBL] [Abstract] [Full Text] [Related]
2. Alternative splicing of NF-YA promotes prostate cancer aggressiveness and represents a new molecular marker for clinical stratification of patients.
Belluti S; Semeghini V; Rigillo G; Ronzio M; Benati D; Torricelli F; Reggiani Bonetti L; Carnevale G; Grisendi G; Ciarrocchi A; Dominici M; Recchia A; Dolfini D; Imbriano C
J Exp Clin Cancer Res; 2021 Nov; 40(1):362. PubMed ID: 34782004
[TBL] [Abstract] [Full Text] [Related]
3. The Diverse Genomic Landscape of Clinically Low-risk prostate cancer.
Cooperberg MR; Erho N; Chan JM; Feng FY; Fishbane N; Zhao SG; Simko JP; Cowan JE; Lehrer J; Alshalalfa M; Kolisnik T; Chelliserry J; Margrave J; Aranes M; Plessis MD; Buerki C; Tenggara I; Davicioni E; Carroll PR
Eur Urol; 2018 Oct; 74(4):444-452. PubMed ID: 29853306
[TBL] [Abstract] [Full Text] [Related]
4. Associations of Luminal and Basal Subtyping of prostate cancer With prognosis and Response to Androgen Deprivation Therapy.
Zhao SG; Chang SL; Erho N; Yu M; Lehrer J; Alshalalfa M; Speers C; Cooperberg MR; Kim W; Ryan CJ; Den RB; Freedland SJ; Posadas E; Sandler H; Klein EA; Black P; Seiler R; Tomlins SA; Chinnaiyan AM; Jenkins RB; Davicioni E; Ross AE; Schaeffer EM; Nguyen PL; Carroll PR; Karnes RJ; Spratt DE; Feng FY
JAMA Oncol; 2017 Dec; 3(12):1663-1672. PubMed ID: 28494073
[TBL] [Abstract] [Full Text] [Related]
